Your browser is no longer supported. Please, upgrade your browser.
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.79 Insider Own0.10% Shs Outstand159.28M Perf Week-6.60%
Market Cap3.11B Forward P/E- EPS next Y-1.24 Insider Trans-47.28% Shs Float158.33M Perf Month-6.01%
Income-281.60M PEG- EPS next Q-0.53 Inst Own95.10% Short Float5.05% Perf Quarter-60.67%
Sales441.80M P/S7.04 EPS this Y-12.00% Inst Trans-0.08% Short Ratio3.09 Perf Half Y-57.49%
Book/sh3.94 P/B4.92 EPS next Y33.20% ROA-36.50% Target Price29.44 Perf Year-59.05%
Cash/sh3.94 P/C4.92 EPS next 5Y25.00% ROE-43.60% 52W Range19.34 - 58.72 Perf YTD-63.71%
Dividend- P/FCF- EPS past 5Y-1.80% ROI-45.80% 52W High-66.96% Beta0.73
Dividend %- Quick Ratio6.70 Sales past 5Y491.50% Gross Margin95.30% 52W Low0.31% ATR0.88
Employees601 Current Ratio6.80 Sales Q/Q23.10% Oper. Margin-64.90% RSI (14)27.82 Volatility3.23% 3.79%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.20% Profit Margin-63.70% Rel Volume0.69 Prev Close19.52
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume2.59M Price19.40
Recom2.50 SMA20-6.60% SMA50-31.42% SMA200-54.12% Volume1,774,220 Change-0.61%
Apr-07-21Downgrade H.C. Wainwright Buy → Neutral $43 → $18
Apr-06-21Downgrade Mizuho Buy → Neutral $37 → $25
Apr-06-21Downgrade Jefferies Buy → Hold $40 → $21
Apr-06-21Downgrade Goldman Buy → Neutral $73 → $25
Apr-06-21Downgrade Canaccord Genuity Buy → Hold $40 → $26
Apr-05-21Downgrade Raymond James Outperform → Mkt Perform
Mar-10-21Downgrade BofA Securities Buy → Neutral
Mar-09-21Reiterated H.C. Wainwright Buy $60 → $43
Mar-09-21Downgrade Stifel Buy → Hold $68 → $27
Mar-09-21Downgrade Raymond James Strong Buy → Outperform $65 → $35
Mar-09-21Downgrade Guggenheim Buy → Neutral
Mar-09-21Downgrade Citigroup Buy → Neutral $66 → $35
Dec-16-20Initiated Mizuho Buy $69
Nov-16-20Upgrade Raymond James Outperform → Strong Buy $65
Aug-25-20Initiated Raymond James Outperform $65
Aug-20-20Initiated Morgan Stanley Overweight $55
Jul-07-20Upgrade Stifel Hold → Buy $41 → $71
Apr-16-20Initiated Jefferies Buy $60
Mar-31-20Upgrade Goldman Neutral → Buy $45 → $72
Mar-06-20Initiated Citigroup Buy $69
May-05-21 10:14PM  
06:39PM  
05:07PM  
04:10PM  
02:45PM  
02:30PM  
02:00PM  
12:10PM  
11:42AM  
May-04-21 03:40PM  
03:00PM  
02:45PM  
02:00PM  
11:30AM  
11:15AM  
11:00AM  
09:00AM  
May-03-21 10:30PM  
09:52PM  
03:37PM  
01:30PM  
06:30AM  
May-02-21 10:42PM  
May-01-21 07:40AM  
Apr-30-21 10:12PM  
02:20PM  
02:15PM  
01:00PM  
12:35PM  
12:30PM  
11:00AM  
11:00AM  
06:30AM  
12:50AM  
Apr-29-21 07:34PM  
05:51PM  
04:15PM  
01:15PM  
11:45AM  
11:00AM  
06:30AM  
Apr-28-21 08:58PM  
08:00PM  
04:00PM  
02:30PM  
01:50PM  
12:33PM  
12:20PM  
11:25AM  
11:03AM  
11:00AM  
11:00AM  
Apr-27-21 06:05PM  
05:25PM  
12:08PM  
10:00AM  
10:00AM  
Apr-26-21 10:51PM  
09:20PM  
03:36PM  
02:42PM  
01:00PM  
11:35AM  
11:30AM  
11:00AM  
06:30AM  
Apr-24-21 11:16PM  
01:45AM  
Apr-23-21 06:38PM  
05:53PM  
05:47PM  
03:34PM  
01:10PM  
12:30PM  
11:45AM  
11:00AM  
11:00AM  
09:45AM  
09:20AM  
Apr-22-21 05:13PM  
04:55PM  
03:43PM  
02:45PM  
02:05PM  
12:35PM  
10:45AM  
10:00AM  
09:32AM  
06:30AM  
Apr-21-21 07:43PM  
07:00PM  
05:47PM  
05:20PM  
04:50PM  
04:48PM  
09:50AM  
09:00AM  
08:45AM  
Apr-20-21 09:00PM  
06:35PM  
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ridloff ElenaEVP and CFOApr 30Sale20.331,03220,98110,553Apr 30 06:55 PM
KIM AUSTIN D.EVP & General CounselApr 30Sale20.331,05421,42811,371Apr 30 06:54 PM
Stankovic Srdjan R.PresidentApr 30Sale20.334,23085,99636,434Apr 30 06:53 PM
DAVIS STEPHENCEOApr 30Sale20.337,850159,59049,312Apr 30 06:52 PM
KIM AUSTIN D.EVP & General CounselFeb 04Sale50.612,107106,6359,911Feb 08 09:00 PM
Stankovic Srdjan R.PresidentFeb 04Sale50.618,429426,59231,049Feb 08 09:00 PM
DAVIS STEPHENCEOFeb 04Sale50.6114,195718,40928,900Feb 08 09:00 PM
Ridloff ElenaEVP and CFOFeb 04Sale50.612,051103,8018,340Feb 08 09:00 PM
Stankovic Srdjan R.PresidentJan 12Option Exercise18.1270012,68420,947Jan 14 07:03 PM
Stankovic Srdjan R.PresidentJan 12Sale55.0170038,50720,247Jan 14 07:03 PM
Stankovic Srdjan R.PresidentJan 08Option Exercise27.4429,733815,98849,980Jan 08 07:28 PM
Stankovic Srdjan R.PresidentJan 08Sale55.2229,7331,641,83220,247Jan 08 07:28 PM
Stankovic Srdjan R.PresidentJan 07Option Exercise35.8061,6192,205,96081,866Jan 08 07:28 PM
Stankovic Srdjan R.PresidentJan 07Sale55.1261,6193,396,18720,247Jan 08 07:28 PM
YANG MICHAEL J.EVP and CCOJan 06Sale53.341,12059,7418,059Jan 08 07:31 PM
KIM AUSTIN D.EVP & General CounselJan 06Sale53.3467836,1655,518Jan 08 07:30 PM
Ridloff ElenaEVP and CFOJan 06Sale53.341,01654,1933,901Jan 08 07:29 PM
Stankovic Srdjan R.PresidentJan 06Sale53.341,72592,01220,247Jan 08 07:28 PM
DAVIS STEPHENCEOJan 06Sale53.343,484185,83724,482Jan 08 07:28 PM
Stankovic Srdjan R.PresidentNov 20Sale53.502,728145,94816,528Nov 20 09:29 PM
KIM AUSTIN D.EVP & General CounselOct 27Option Exercise17.588,750153,82512,601Oct 29 04:12 PM
KIM AUSTIN D.EVP & General CounselOct 27Sale45.108,750394,6363,851Oct 29 04:12 PM
YANG MICHAEL J.EVP and CCOOct 16Sale42.561,24753,0726,457Oct 19 05:27 PM
Stankovic Srdjan R.PresidentOct 16Sale42.561,29755,20013,006Oct 19 05:26 PM
DAVIS STEPHENCEOOct 16Sale42.562,960125,97814,786Oct 19 05:25 PM
YANG MICHAEL J.EVP and CCOJul 07Option Exercise23.0027,250626,77032,454Jul 09 06:26 PM
YANG MICHAEL J.EVP and CCOJul 07Sale56.2527,2501,532,7865,204Jul 09 06:26 PM
Stankovic Srdjan R.PresidentJun 19Option Exercise18.1216,452298,11027,786Jun 19 06:55 PM
Stankovic Srdjan R.PresidentJun 19Sale50.1216,452824,51511,334Jun 19 06:55 PM
Stankovic Srdjan R.PresidentJun 18Option Exercise18.8165,8431,238,69777,177Jun 19 06:55 PM
Stankovic Srdjan R.PresidentJun 18Sale50.0165,8433,292,72911,334Jun 19 06:55 PM
DAVIS STEPHENCEOMay 14Option Exercise19.6588,5421,739,850100,351May 15 07:11 PM
DAVIS STEPHENCEOMay 14Sale45.6288,5424,039,10511,809May 15 07:11 PM
DAVIS STEPHENCEOMay 13Option Exercise19.65111,4582,190,150123,267May 15 07:11 PM
DAVIS STEPHENCEOMay 13Sale46.35111,4585,165,58711,809May 15 07:11 PM
Daly James MDirectorMay 11Option Exercise26.3926,250692,70026,250May 13 06:00 PM
Daly James MDirectorMay 11Sale51.1326,2501,342,1780May 13 06:00 PM